Is your shoulder cartilage damage suitable for a ChondroFiller injection?

Roughly speaking, a clinician looks for four things before confirming candidacy: the right lesion grade, the right defect size, a structurally sound joint environment, and imaging that confirms all three.

Lesion grade. ChondroFiller injection is designed for Grade III or IV cartilage damage — loss of more than half the cartilage thickness, or exposure of the underlying subchondral bone. Superficial or partial-thickness wear is outside this indication; so is damage so advanced that the joint has lost most of its cartilage across multiple surfaces.

Defect size. Focal lesions of approximately 1.5–6 cm² are the target window. The manufacturer's clinical evidence report supports this range, with published studies typically centring on defects of around 2–3 cm². Lesions outside this window carry less predictable results.

Joint environment. The glenohumeral joint must be structurally sound enough to support regeneration. Generalised osteoarthritis, bone-on-bone wear, significant ligamentous instability, and gross mechanical malalignment are all exclusions — the scaffold cannot compensate for a joint environment that cannot sustain it. A prospective hip cohort confirmed this principle directly: patients with Tönnis Grade 2–3 pre-existing OA had poor outcomes regardless of individual defect characteristics, establishing a hard clinical boundary that applies equally to the shoulder.

The role of MRI. The shoulder is explicitly listed by the manufacturer as an indicated joint, alongside the knee, hip, and ankle. Manufacturer indication is not, however, the same as individual candidacy. An MRI is the step that converts an informal 'I might be suitable' into a clinically grounded answer — confirming lesion grade, defect geometry, and the condition of the surrounding cartilage and bone before any treatment decision is made. No clinical assessment alone is sufficient to establish this.

What the ChondroFiller collagen scaffold is — and what it is not

Several injections are used in shoulder care — corticosteroids for inflammation, hyaluronic acid for lubrication, PRP for biologic support — but ChondroFiller does something structurally different from all of them. It is a CE-marked Class III medical device: an acellular collagen Type I hydrogel that acts as a three-dimensional scaffold, not a lubricant, painkiller, or cosmetic filler.

The delivery system is a two-chamber syringe. When the two solutions pass through a mixing adapter, they combine at the needle tip and self-gel within approximately 3–5 minutes inside the defect, conforming precisely to its geometry. No bone drilling, no fibrin glue, and no donor cells are required.

What drives the repair is matrix-induced chondrogenesis: once the scaffold is in place, the patient's own progenitor cells — drawn from the synovial lining and the subchondral bone — migrate into the collagen matrix and progressively differentiate into chondrocytes. A 2025 ex vivo osteochondral study recorded a 2.4-fold increase in DNA content within the ChondroFiller group by day 14, providing direct laboratory confirmation that this endogenous cell recruitment happens without any exogenous cells being introduced.

This biology cannot be rushed. The injection initiates the scaffold; the tissue that replaces it builds over 6–24 months. Patients should expect a gradual, progressive improvement rather than an immediate structural change.

How ChondroFiller injection is delivered in the shoulder

On the day of treatment, patients attend a 30–45 minute outpatient appointment at the London Cartilage Clinic on Harley Street — no general anaesthetic, no surgical incision, and no overnight stay. The ChondroFiller injection is placed under real-time ultrasound guidance, after which patients leave the same day.

That ultrasound guidance is clinically essential rather than a convenient add-on. The glenohumeral joint sits deep within the shoulder, enclosed by a complex arrangement of muscles, tendons, and the joint capsule itself. Intracapsular access requires threading the needle through a precise anatomical corridor to reach the defect — a landmark-only technique cannot reliably achieve that placement, and an injection that misses the lesion delivers no structural benefit.

The shoulder's biomechanics also differ meaningfully from the knee or hip. As a non-weight-bearing joint, it is spared the cyclic compressive loads that act on the lower limb — an advantage during the early phase when the scaffold is still maturing. However, the glenohumeral articulation generates substantial rotational and shear forces through everyday arm movement, which is why post-injection rehabilitation must progress carefully through passive range of motion before active loading.

Technique sensitivity matters throughout. Research has shown that overfilling a defect — rather than applying the gel flush with the surrounding cartilage surface — produces fibrous rather than hyaline-like tissue. Getting the volume and placement right is therefore as important as the product itself, which is why consistent outcomes depend on experienced, image-guided delivery.

What the clinical evidence shows — and where the gaps are

No published clinical cohort has specifically studied ChondroFiller injection in the glenohumeral joint. That gap should be named directly: shoulder-specific outcome data does not yet exist, and any honest assessment of the evidence must start there.

The most relevant proxy comes from a prospective hip cohort — a joint that, like the shoulder, is non-axial and subject to shear rather than sustained compressive loading. In this study, 26 adults with acetabular cartilage lesions larger than 2 cm² received ChondroFiller; at follow-up ranging from 12 to 60 months, 17 of the 21 evaluable patients achieved good or excellent results, with MRI confirming cartilage healing. The hip cohort also established a hard clinical boundary that maps directly onto shoulder candidacy: patients with pre-existing Tönnis Grade 2–3 osteoarthritis — indicating widespread joint deterioration — had poor outcomes, reinforcing why generalised OA remains an exclusion.

For functional outcome data, a 2016 randomised multicentre knee study showed statistically significant IKDC score gains at 3, 6, and 12 months, with MRI demonstrating progressive defect integration over time. A 2024 knee series corroborated those functional improvements in a real-world setting.

The most objective histological evidence comes from a 2025 wrist arthroscopy study (n=25 treated patients), where second-look arthroscopy found median Outerbridge scores of 1.5 in the ChondroFiller group versus 3 in controls (P=0.006) — a statistically significant difference in cartilage quality at the tissue level.

Taken together, these studies support the biological plausibility of ChondroFiller injection for focal glenohumeral lesions in appropriately selected patients. They cannot, however, substitute for shoulder-specific trial data, and clinicians and patients should weigh them accordingly.

Recovery timeline and what to expect aftertreatment

Patience is built into this treatment by biology, not by convention. A 2024 biomechanical study found that ChondroFiller does not shield the opposing cartilage surface from load damage during its initial uncured phase — meaning the scaffold needs time to set and integrate before the shoulder is used normally. That finding is the direct rationale for the loading restrictions that follow injection, not a general precaution.

For the shoulder, rehabilitation progresses in stages: passive range of motion first, then active movement, then resistance and overhead loading. The precise schedule is set by the treating clinician based on defect size, location, and individual healing response — no fixed timetable replaces that clinical judgement.

Full tissue regeneration takes anywhere from 6 to 24 months. That is a wide range, and it reflects genuine biological variation: defect size, the patient's age and activity level, and the rate at which progenitor cells populate and mature within the scaffold all influence the timeline. Symptom changes — or the absence of them — in the first few weeks do not signal success or failure; the process is simply too early to read.

MRI is the standard tool for assessing scaffold fill and tissue maturation at agreed intervals after treatment. Physiotherapy is a core component of the pathway rather than an optional extra, and returning to sport or sustained overhead activity before the scaffold has matured risks compromising the result.

Pricing, availability, and booking an assessment

Access to ChondroFiller injection in the UK is currently through the London Cartilage Clinic on Harley Street, which operates as the UK's certified delivery centre for the product.

Pricing starts at £3,000 for a single box and is inclusive of the clinical consultation, ultrasound guidance, the ChondroFiller product itself, and a six-week follow-up appointment. Larger defects or those spanning more than one compartment may require two boxes (£5,500) or three (£8,000). This is a self-funded private treatment; ChondroFiller injection is not available on the NHS and is not currently reimbursed by standard UK private medical insurance. The product is CE-marked for use in the UK and select European specialist centres but is not FDA-approved and is not available in the United States.

The appropriate first step before any treatment decision is a clinical assessment — MRI review to confirm defect grade, size, and the condition of the surrounding joint, combined with clinical examination to establish candidacy.

Book an assessment at the London Cartilage Clinic via londoncartilage.com.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
3. [3] Controlled, randomized multicenter study: ChondroFiller liquid vs microfracturing for focal knee cartilage defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
5. [5] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z